-
MS170 is a CRBN-recruiting degrader, the AKT proteolysis targeting chimera (PROTAC) degrader. -
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR. -
Lomeguatrib is a highly potent MGMT inactivator, improves the therapeutic effect of alkylating agents in a number of tumour models. -
VAL-083 is an alkylating agent that creates N7 methylation on DNA, VAL-083 exhibits antitumor activity in vitro and in vivo. -
Hesperadin, an ATP competitive inhibitor of Aurora A/B, inhibits Aurora B with an IC50 of 250 nM. A broad-spectrum influenza antiviral. -
PFM39 is a potent and selective MRE11 exonuclease inhibitor, and does not inhibit endonuclease, nuclease activity. -
HM43239 is a potent, selective, and orally active FLT3 inhibitor and shows effectiveness in AML with FLT3 mutations. -
GS-493 is a selective SHP2 inhibitor and blocks cellular motility and growth of cancer cells in vitro and in vivo.
Categories
Diseases
Others
Archives
- March 2023 (14)
- February 2023 (18)
- January 2023 (14)
- December 2022 (21)
- November 2022 (14)
- October 2022 (16)
- September 2022 (13)
- August 2022 (13)
- July 2022 (12)
- June 2022 (12)
- May 2022 (13)
- April 2022 (10)
- March 2022 (9)
- February 2022 (8)
- January 2022 (14)
- December 2021 (13)
- November 2021 (13)
- October 2021 (13)
- September 2021 (11)
- August 2021 (17)
- July 2021 (19)
- June 2021 (18)
- May 2021 (18)
- April 2021 (17)
- March 2021 (19)
- February 2021 (16)
- January 2021 (20)
- December 2020 (16)
- November 2020 (16)
- October 2020 (17)
- September 2020 (18)
- August 2020 (17)
- July 2020 (18)
- June 2020 (17)
- May 2020 (17)
- April 2020 (18)
- March 2020 (17)
- February 2020 (14)
- January 2020 (16)
- December 2019 (19)
- November 2019 (15)
- October 2019 (17)
- September 2019 (28)
- August 2019 (31)
- July 2019 (31)
- June 2019 (32)
- May 2019 (31)
- April 2019 (32)
- March 2019 (7)
